Skip to main content
Fig. 7 | COPD Research and Practice

Fig. 7

From: Lung hyperinflation in COPD: applying physiology to clinical practice

Fig. 7

Improvements in response to long-acting ß2-agonists (LABA), long-acting muscarinic antagonists (LAMA) and LABA/LAMA combinations compared with placebo are shown for exercise measurements of inspiratory capacity (IC) at a standardized time during exercise (isotime), constant-work rate cycle exercise endurance time, and dyspnea intensity ratings at isotime. Treatment differences in these randomized, placebo-controlled studies are statistically significant (p < 0.05) unless indicated otherwise (NS, not significant)

Back to article page